8-K: Arvinas Unveils Promising Preclinical Data for Novel Lymphoma Degrader ARV-393 at EHA 2025 Congress

Arvinas, Inc. announced encouraging preclinical results for its investigational PROTAC BCL6 degrader, ARV-393, demonstrating significant single-agent activity and enhanced efficacy in combination therapies for various non-Hodgkin lymphoma subtypes.

Summary

• Arvinas, Inc. presented positive preclinical data for ARV-393, an investigational PROTAC BCL6 degrader, at the European Hematology Association (EHA) 2025 Congress in Milan, Italy.
• ARV-393 demonstrated significant single-agent activity in a patient-derived xenograft (PDX) model of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (nTFHL-AI, also known as AITL), derived from a patient who relapsed post-chemotherapy.
• Monotherapy with ARV-393 resulted in robust (95%) tumor growth inhibition (TGI) in two PDX models of transformed follicular lymphoma (tFL).
• In combination with five classes of oral small molecule inhibitors (SMIs) – tazemetostat, palbociclib, everolimus, acalabrutinib, or venetoclax – ARV-393 showed increased TGI and tumor regressions in cell line-derived xenograft (CDX) models of high-grade B-cell lymphoma (HGBCL) and aggressive diffuse large B-cell lymphoma (DLBCL).
• RNA sequencing studies suggest ARV-393 inhibits tumor cell cycle progression and promotes differentiation, contributing to its antitumor activity and broad combinability in preclinical models.
• A Phase 1 study of ARV-393 is currently enrolling adult patients with relapsed/refractory non-Hodgkin lymphoma, including DLBCL and nTFHL-Al (AITL).

Sentiment

Score: 8

Explanation: The document presents strong positive preclinical data for ARV-393, demonstrating significant single-agent activity and enhanced efficacy in combination therapies for various aggressive lymphoma subtypes. This represents a de-risking event for the program and supports its progression into clinical trials, indicating a highly favorable outlook for this specific drug candidate.

Positives

• ARV-393 showed significant single-agent activity in a patient-derived xenograft model of nTFHL-AI (AITL), a challenging lymphoma subtype.
• The data represents potentially the first preclinical evidence of anti-tumor activity with an efficacious BCL6-targeted small-molecule degrader in a human nTFHL-AI model.
• ARV-393 monotherapy achieved robust 95% tumor growth inhibition in two transformed follicular lymphoma (tFL) PDX models.
• Combination therapies with ARV-393 and five different small molecule inhibitors demonstrated enhanced antitumor activity, including observed tumor regressions, in models of high-grade B-cell lymphoma (HGBCL) and aggressive diffuse large B-cell lymphoma (DLBCL).
• The mechanism of action, involving inhibition of tumor cell cycle progression and promotion of differentiation, suggests broad utility and combinability for ARV-393.

Risks

• Forward-looking statements involve substantial risks and uncertainties, and the company may not achieve its disclosed plans, intentions, or expectations.
• Actual results or events could differ materially from forward-looking statements due to various risks and uncertainties.
• Drug development inherently carries risks, including unexpected costs or delays in clinical trials.
• Positive data from preclinical or early clinical studies are not necessarily predictive of the results of later clinical studies.
• The company's ability to protect its intellectual property portfolio is crucial for its success.
• Reliance on third parties for various aspects of drug development and commercialization poses risks.
• There is a risk regarding the company's ability to raise capital when needed.
• The sufficiency of the company's cash and cash equivalents to fund foreseeable and unforeseeable operating expenses and capital expenditure requirements is a risk factor.

Future Outlook

The company believes these preclinical data for ARV-393 potentially suggest broad utility across non-Hodgkin lymphoma subtypes with unmet medical needs beyond diffuse large B-cell lymphoma (DLBCL). This provides a compelling rationale for considering combination strategies, including chemotherapy-free approaches, as Arvinas works to bring forward new therapeutic options for adult patients with lymphoma. A Phase 1 study of ARV-393 is currently enrolling patients.

Management Comments

• "We are encouraged by the marked single-agent activity of ARV-393 in PDX models of AITL and transformed follicular lymphoma and by the enhanced antitumor activity of ARV-393 in combination with five classes of small molecule inhibitors in models of aggressive DLBCL." Noah Berkowitz, M.D., Ph.D., Chief Medical Officer at Arvinas.
• "We believe these preclinical data potentially suggest the broad utility of ARV-393 across non-Hodgkin lymphoma subtypes with unmet need beyond DLBCL and provide a compelling rationale for considering combination strategies including chemotherapy-free approaches as we work to bring forward new therapeutic options for adult patients with lymphoma." Noah Berkowitz, M.D., Ph.D., Chief Medical Officer at Arvinas.

Industry Context

This announcement highlights Arvinas' continued progress in the targeted protein degradation space, a novel therapeutic modality. The positive preclinical data for ARV-393 in various non-Hodgkin lymphoma subtypes, particularly in patient-derived models and in combination with existing small molecule inhibitors, positions it as a promising candidate in an area with significant unmet medical need. The focus on BCL6 degradation offers a new approach to treating these aggressive lymphomas, potentially expanding treatment options beyond current standards and exploring chemotherapy-free regimens.

Comparison to Industry Standards

• The document states that the single-agent activity of ARV-393 in the nTFHL-AI (AITL) PDX model is 'potentially the first preclinical evidence of anti-tumor activity with an efficacious BCL6-targeted small-molecule degrader in a human nTFHL-AI model,' suggesting a novel and potentially leading position in this specific indication for BCL6 degraders.
• The robust 95% tumor growth inhibition in tFL models and observed tumor regressions in HGBCL and DLBCL models when combined with established SMIs (like tazemetostat, palbociclib, acalabrutinib, or venetoclax) indicate strong preclinical efficacy that could compare favorably to other investigational agents or even current standards, especially given the novel PROTAC mechanism.

Stakeholder Impact

• Shareholders: Positive preclinical data could lead to increased investor confidence and potential share price appreciation due to de-risking of the drug candidate and its potential market.
• Patients: The development of ARV-393 offers potential new therapeutic options, including chemotherapy-free approaches, for adult patients suffering from relapsed/refractory non-Hodgkin lymphoma, particularly those with unmet needs in subtypes like AITL and tFL.
• Employees: Continued positive drug development supports job security and potential growth opportunities within the company.
• Healthcare Providers: If successful, ARV-393 could provide new tools for treating aggressive lymphomas, expanding the armamentarium of available therapies.

Next Steps

• Continue enrollment of adult patients in the Phase 1 clinical study of ARV-393 for relapsed/refractory non-Hodgkin lymphoma, including DLBCL and nTFHL-Al (AITL) (NCT06393738).
• Further explore combination strategies, including chemotherapy-free approaches, for ARV-393 in non-Hodgkin lymphoma subtypes.

Key Dates

Recommendation

Keywords

Arvinas, ARV-393, PROTAC, BCL6 degrader, Non-Hodgkin lymphoma, DLBCL, AITL, nTFHL-AI, Transformed follicular lymphoma, tFL, Preclinical data, Oncology, Targeted protein degradation, Biotechnology, Clinical-stage, Hematology